Fig 3. Cost-effectiveness & cost-utility acceptability curves (CEACs) with 7-day point prevalence abstinence, quality of life measured with the ICECAP, and quality of life measured with the EuroQoL assessed at six-month follow-up as outcomes (primary analysis).